Thank you - Your Download is Available Below
Accelerating T Cell Manufacturing Immunotherapy With Nutri-T ACF Medium
The development of T cell-based immunotherapies like chimeric antigen receptor (CAR) T cells and tumor-infiltrating lymphocytes (TILs) has shown great promise in cancer treatment. However, robust manufacturing of T cell products faces challenges including variability of cellular starting material and the use of human serum-containing media. This study present 4Cell® Nutri-T Advanced Medium, a novel Animal Component-Free (ACF) medium, tailored for the expansion of T cells from healthy donors and cancer patients.
4Cell® Nutri-T Advanced Medium consists of recombinant proteins and other defined pharmaceutical-grade components optimized to promote rapid T cell proliferation. The exclusion of components originating from human and animals ensures ethical procurement and augments patient safety. The medium underwent systematic examination utilizing diverse culture systems, including conventional plastic culture ware, gas-permeable systems (G-Rex), spinners, and small-scale bioreactors. T cells from both healthy donors and cancer patients were expanded in 4Cell® Nutri-T Advanced Medium in comparison to other ACF formulations as well as conventional serum-containing media.
Results indicate the outstanding performance of 4Cell® Nutri-T Advanced Medium, demonstrating high fold expansion for both healthy and patient T cells. Importantly, it maintained a naive and cytotoxic T cell phenotype ideal for cell therapy. In terms of functionality, T cells expanded in 4Cell® Nutri-T Advanced Medium exhibited potent target cell killing and enabled efficient CAR transduction and expansion of the engineered T cells, all accomplished within a regulatory-friendly environment.
In summary, 4Cell® Nutri-T Advanced Medium exhibits optimal performance specially tailored for T cell manufacture. By enabling a reliable and scalable expansion of T cells, this advanced ACF medium holds the potential to significantly streamline the efficient production of quality-assured T cells for immunotherapy, ultimately enhancing patient outcomes.
